In vivo fluorescence lifetime imaging of tumor xenografts displaying differences in the amounts and distributions of TME components, such as collagen and vascularity, revealed a difference in distribution of trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor (HER2), underlying the role of TME in drug availability within tumor [95]. The gene discussed is ERBB2; the disease is neoplasm.